No More Headaches For Zosana Pharma?

Zosano Pharma Corp (ZSAN) shares rose dramatically today due to the news that the company met the final milestones for its long-term safety study of Qtrypta, an acute treatment for migraine disease. The stock moved up over +180% on extremely high volume, with very little hesitation along the way. Here’s a recap.